Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference
06 Setembro 2023 - 5:10PM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced the company will be
participating in the upcoming Morgan Stanley 21st Annual Global
Healthcare Conference in New York, New York.
Cytek management is scheduled to participate in a fireside chat
on Wednesday, September 13th at 4:15 p.m. Eastern Time / 1:15 p.m.
Pacific Time. Interested parties may access a live and archived
webcast of the presentation on the “Investors” section of the
company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.Cytek Biosciences
(Nasdaq: CTKB) is a leading cell analysis solutions company
advancing the next generation of cell analysis tools by delivering
high-resolution, high-content and high-sensitivity cell analysis
utilizing its patented Full Spectrum Profiling™ (FSP™) technology.
Cytek’s novel approach harnesses the power of information within
the entire spectrum of a fluorescent signal to achieve a higher
level of multiplexing with precision and sensitivity. Cytek’s FSP
platform includes its core instruments, the Aurora and Northern
Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer
and imaging products under the Amnis® and Guava® brands; and
reagents, software and services to provide a comprehensive and
integrated suite of solutions for its customers. Cytek is
headquartered in Fremont, California with offices and distribution
channels across the globe. More information about the company and
its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain
reagents for use therewith, which are available for clinical use in
countries where the regulatory approval has been obtained from the
local regulatory authorities, including China and the European
Union, Cytek’s products are for research use only and not for use
in diagnostic procedures.
Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and
Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page
and corporate “X” (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Media Contact:Stephanie OlsenLages &
Associates(949) 453-8080stephanie@lages.com
Investor Relations Contact:Paul D. GoodsonHead
of Investor Relationspgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024